Key current clinical issues in alpha-1 antitrypsin deficiency

Respiratory Care

Volumn 48, Issue 12, 2003, Pages 1216-1221

  Stoller, James K ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Alpha 1 antitrypsin deficiency; Chronic obstructive pulmonary disease; COPD

Indexed keywords

ALPHA 1 ANTITRYPSIN;

AIRWAY OBSTRUCTION; ALPHA 1 ANTITRYPSIN DEFICIENCY; ASTHMA; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL PRACTICE; CONFERENCE PAPER; FORCED EXPIRATORY VOLUME; GENETIC ANALYSIS; HUMAN; MEDICAL DOCUMENTATION; OCCUPATIONAL EXPOSURE; PRACTICE GUIDELINE; SCREENING; ADOLESCENT; ADULT; CLINICAL PROTOCOL; INTRAVENOUS DRUG ADMINISTRATION; MASS SCREENING; NEWBORN; REVIEW; STANDARD; TREATMENT OUTCOME;

ADOLESCENT; ADULT; ALPHA 1-ANTITRYPSIN; ALPHA 1-ANTITRYPSIN DEFICIENCY; CLINICAL PROTOCOLS; HUMANS; INFANT, NEWBORN; INFUSIONS, INTRAVENOUS; MASS SCREENING; TREATMENT OUTCOME;

EID: 2342458506     PISSN: 00201324     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (28)

1. Carrell RW, Lomas DA. Alpha1-antitrypsin deficiency: a model for conformational diseases. N Engl J Med 2002;346(1):45-53.
2. Stoller JK. Clinical manifestations and natural history of alpha-1-antitrypsin deficiency. UpToDate Volume 11.1, 2003.
3. Rovner MS, Stoller JK. Treatment of alpha 1-antitrypsin deficiency. UpToDate Volume 11.1, 2003.
4. Crystal RG. Alpha 1-antitrypsin deficiency, emphysema, and liver disease: genetic basis and strategies for therapy. J Clin Invest 1990;85(5):1343-1352.
5. Stoller JK, Snider GL, Brantly M, Fallat RA, Stockley R, and the Alpha-1 Antitrypsin Deficiency Task Force. Standards for the diagnosis and management of individuals with alpha-1 antitrypsin (AAT) deficiency. Am J Respir Crit Care Med 2003;168(7):818-900.
6. American Thoracic Society. Guidelines for the approach to the patient with severe hereditary alpha-1-antitrypsin deficiency. Am Rev Respir Dis 1989;140(5):1494-1497.
7. Ad Hoc Committee on Alpha-1-Antitrypsin Replacement Therapy of the Standards Committee, Canadian Thoracic Society. Current status of alpha-1-antitrypsin replacement therapy: recommendations for the management of patients with severe hereditary deficiency. CMAJ 1992;146(6):841-844.
8. Abboud RT, Ford GT, Chapman KR; Standards Committee of the CanadianThoracic Society. Alpha1-antitrypsin deficiency: a position statement of the Canadian Thoracic Society. Can Respir J 2001;8(2):81-88.
9. Pauwels RA, Buist AS, Calverley PM, Jenkins CR, Hurd SS; GOLD Scientific Committee. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. Am J Respir Crit Care Med 2001;163(5):1256-1276.
10. U. S. Preventive Services Task Force. Guide to clinical prevention services: report to the U. S. Preventive Services Task Force, 2nd ed. Baltimore: Williams & Wilkins; 1996:231-246.
11. Stoller JK, Smith P, Yang P, Spray J. Physical and social impact of alpha 1-antitrypsin deficiency: results of a survey. Cleve Clin J Med 1994;61(6):461-467.
12. Sveger T, Piitulainen E, Arborelius M Jr. Clinical features and lung function in 18-year old adolescents with alpha 1-antitrypsin deficiency. Acta Paediatr 1995;84(7):815-816.
13. Wall M, Moe E, Eisenberg J, Powers M, Buist N, Buist AS. Long-term follow-up of a cohort of children with alpha-1-antitrypsin deficiency. J Pediatr 1990;116(2):248-251.
14. Mayer AS, Stoller JK, Bucher Bartelson B, Ruttenber AJ, Sandhaus RA, Newman LS. Occupational exposure risks in individuals with PI*ZZ alpha-1 antitrypsin deficiency. Am J Respir Crit Care Med 2000;162(2Pt1):553-558.
15. Piitulainen E, Tornling G, Eriksson S. Effect of age and occupational exposure to airway irritants on lung function in non-smoking individuals with alpha 1-antitrypsin deficiency (PiZZ). Thorax 1997;52(3):244-248.
16. Minai OA, Stoller JK. Therapy for alpha 1-antitrypsin deficiency: pharmacology and clinical recommendations. BioDrugs 2000;13:135-147.
17. Wewers MD, Casolaro MA, Sellers SE, Swayze S, McPhaul KM, Wittes JT, Crystal RG. Replacement therapy for alpha 1-antitrypsin deficiency associated with emphysema. N Engl J Med 1987;316(17):1055-1062.
18. Hubbard, RC, Crystal, RG. Alpha-1-antitrypsin augmentation therapy for alpha-1-antitrypsin deficiency. Am J Med 1988;84(6A):52-62.
19. Seersholm N, Kok-Jensen A, Dirksen A. Decline in FEV1 among patients with severe hereditary alpha 1-antitrypsin deficiency type PiZ. Am J Respir Crit Care Med 1995;152(6 Pt 1):1922-1925.
20. The Alpha-1-Antitrypsin Deficiency Registry Study Group. Survival and FEV1 decline in individuals with severe deficiency of alpha1-antitrypsin. Am J Respir Crit Care Med 1998;158(1):49-59.
21. American Thoracic Society. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1995;152(5 Pt 2):S77-S121.
22. Dirksen A, Dijkman JH, Madsen F, Stoel B, Hutchison DCS, Ulrik CS, et al. A randomized clinical trial of alpha 1-antitrypsin augmentation therapy. Am J Respir Crit Care Med 1999;160(5 Pt 1):1468-1472.
23. Wencker M, Banik N, Buhl R, Seidel R, Konietzko N. Long-term treatment of alpha1-antitrypsin deficiency-related pulmonary emphysema with human alpha1-antitrypsin. Eur Respir J 1998;11(2):428-433.
24. Lieberman J. Augmentation therapy reduces frequency of lung infections in antitrypsin deficiency: a new hypothesis with supporting data. Chest 2000;118(5):1480-1485.
25. Stoller JK, Fallat R, Schluchter MD, O'Brien RG, Connor JT, Gross N, et al. Augmentation therapy with alpha 1-antitrypsin: patterns of use and adverse reactions. Chest 2003;123(5):1425-1434.
26. The Alpha 1-Antitrypsin Deficiency Registry Study Group. A registry of patients with severe deficiency of alpha 1-antitrypsin: design and methods. Chest 1994;106 (4):1223-1232.
27. Song S, Embury J, Laipis PJ, Berns KI, Crawford JM, Flotte TR. Stable therapeutic serum levels of human alpha-1 antitrypsin (AAT) after portal vein injection of recombinant adeno-associated virus (rAAV) vectors. Gene Ther 2001;8(17):1299-1306.
28. Song S, Scott-Jorgensen M, Wang J, Poirier A, Crawford J, Campbell-Thompson M, Flotte TR. Intramuscular administration of recombinant adeno-associated virus 2 alpha-1 antitrypsin (rAAV-SERPINA1) vectors in a nonhuman primate model: safety and immunologic aspects. Mol Ther 2002;6(3):329-335.